Last reviewed · How we verify
NCT05211830
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome
Phase 1, PHASE2 trial testing SXR1096 cream in Netherton Syndrome in 9 participants. Completed in 20 August 2025.
10 June 2025
Quick facts
| Lead sponsor | Sixera Pharma |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 7 December 2021 |
| Primary completion | 10 June 2025 |
| Estimated completion | 20 August 2025 |
| Sites | 5 locations across Austria, France, Germany, Sweden |
Drugs / interventions tested
- SXR1096 cream — full drug profile →
- Placebo cream
Conditions studied
- Netherton Syndrome — all drugs for Netherton Syndrome →
Sponsor
Sixera Pharma — full company profile →
Who can join
12 and older, any sex, with Netherton Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this phase I/II trial a topical skin cream with the active substance SXR1096 will be tested in patients with Netherton syndroms, a rare inflammatory skin disease. SXR1096 is a specific and potent protease inhibitor that can inhibit the proteases kallikrein 5, 7 and 14 - all recognised as up-regulated and causing the disease state in Netherton syndrome patients. Patients will be treated for one month with active cream and placebo cream at different areas of the skin.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
New developments in the molecular treatment of ichthyosis: review of the literature.
Joosten MDW, Clabbers JMK, Jonca N, Mazereeuw-Hautier J, et al · · 2022 · cited 38× · PMID 35840979 · DOI 10.1186/s13023-022-02430-6 -
Dysregulated proteolytic cascades in Netherton syndrome: from molecular pathology to preclinical drug testing.
Zingkou E, Bisyris E, Pampalakis G, Sotiropoulou G. · · 2026 · PMID 41511866 · DOI 10.1002/path.70018
Verify or expand the search:
- PubMed search for NCT05211830
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Netherton Syndrome
Currently open trials in the same condition.
- NCT06137157 — Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome · Phase 1 · recruiting
- NCT05789056 — Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome · Phase 2, PHASE3 · recruiting
- NCT05521438 — Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome · Phase 2, PHASE3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05211830 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sixera Pharma
- Last refreshed: 16 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05211830.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing